Collins C. James's Insider Trades & SAST Disclosures
Collins C. James's most recent trade in Archer Daniels Midland Co. was a trade of 1,065 Stock Units done . Disclosure was reported to the exchange on April 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Collins C. James.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 1,065 | 8,463 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 75 | 7,398 | - | - | Stock Units | |
| Senti Biosciences Inc. | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 43,900 | 43,900 | - | - | Stock Option (Right to Buy) | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 1,020 | 7,322 | - | - | Stock Units | |
| Archer Daniels Midland Co. | Collins C. James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 59 | 6,302 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 857 | 6,243 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2024 | 45 | 5,386 | - | - | Stock Units | |
| Senti Biosciences Inc. | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2024 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 846 | 5,341 | - | - | Stock Units | |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 36 | 4,495 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 793 | 4,458 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James Collins C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 34 | 3,665 | - | - | Stock Units | |
| Archer Daniels Midland Co. | C. James Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 693 | 3,631 | - | - | Stock Units | |
| Archer Daniels Midland Co. | C. Collins James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 17 | 2,937 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2023 | 661 | 2,920 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2023 | 13 | 2,258 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 667 | 2,245 | - | - | Stock Units | |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Senti Biosciences Inc. | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 62,500 | 62,500 | - | - | Stock Option (Right to Buy) | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 9 | 1,578 | - | - | Stock Units | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 27 Apr 2023 | 1,000 | 125,288 (0%) | 0% | 11.5 | 11,490 | Common Stock | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 626 | 1,569 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 5 | 942 | - | - | Stock Units | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 31 Jan 2023 | 3,000 | 124,288 (0%) | 0% | 0 | Common Stock | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 17 Jan 2023 | 1,000 | 0 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 17 Jan 2023 | 1,000 | 121,288 (0%) | 0% | 9.0 | 9,030 | Common Stock | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 540 | 937 | - | - | Stock Units | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2022 | 1 | 397 | - | - | Stock Units | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 9,000 | 108,288 (0%) | 0% | 9.0 | 81,270 | Common Stock | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 9,000 | 1,000 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 6,000 | 4,000 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 6,000 | 4,000 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 6,000 | 120,288 (0%) | 0% | 10.9 | 65,520 | Common Stock | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Nov 2022 | 6,000 | 114,288 (0%) | 0% | 10.8 | 64,860 | Common Stock | |
| Archer Daniels Midland Co. | James C. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2022 | 395 | 395 | - | - | Stock Units | |
| Senti Biosciences Inc. | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2022 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 12 Jan 2022 | 3,000 | 99,288 (0%) | 0% | 0 | Common Stock | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Sep 2021 | 500 | 96,288 (0%) | 0% | 8.9 | 4,465 | Common Stock | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 29 Sep 2021 | 500 | 0 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 19 Aug 2021 | 4,000 | 95,788 (0%) | 0% | 8.9 | 35,720 | Common Stock | |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 19 Aug 2021 | 4,000 | 500 | - | - | Stock Options | ||
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 165,563 | 331,126 | - | - | Non-Qualified Stock Options | |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.22 per share. | 10 Aug 2021 | 165,563 | 491,590 (0%) | 0% | 31.2 | 5,168,877 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.43 per share. | 10 Aug 2021 | 113,777 | 377,813 (0%) | 0% | 45.4 | 5,168,889 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.94 per share. | 10 Aug 2021 | 75,463 | 398,357 (0%) | 0% | 41.9 | 3,164,918 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 75,463 | 0 | - | - | Non-Qualified Stock Options | |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.43 per share. | 10 Aug 2021 | 69,666 | 328,691 (0%) | 0% | 45.4 | 3,164,926 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.43 per share. | 10 Aug 2021 | 23,796 | 354,017 (0%) | 0% | 45.4 | 1,081,052 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.43 per share. | 10 Aug 2021 | 2,664 | 326,027 (0%) | 0% | 45.4 | 121,026 | Common Stock |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 131,943 | 0 | - | - | Non-Qualified Stock Options | |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.68 per share. | 18 May 2021 | 131,943 | 436,781 (0%) | 0% | 34.7 | 4,575,783 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.00 per share. | 18 May 2021 | 99,486 | 337,295 (0%) | 0% | 46.0 | 4,575,859 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.76 per share. | 18 May 2021 | 82,464 | 368,664 (0%) | 0% | 26.8 | 2,206,737 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 82,464 | 0 | - | - | Non-Qualified Stock Options | |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.99 per share. | 18 May 2021 | 47,979 | 320,685 (0%) | 0% | 46.0 | 2,206,794 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 27,837 | 0 | - | - | Non-Qualified Stock Options | |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.36 per share. | 18 May 2021 | 27,837 | 309,577 (0%) | 0% | 32.4 | 900,805 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.99 per share. | 18 May 2021 | 19,585 | 289,992 (0%) | 0% | 46.0 | 900,812 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.00 per share. | 18 May 2021 | 15,847 | 304,838 (0%) | 0% | 46.0 | 728,883 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.99 per share. | 18 May 2021 | 14,915 | 322,380 (0%) | 0% | 46.0 | 686,015 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.99 per share. | 18 May 2021 | 3,792 | 286,200 (0%) | 0% | 46.0 | 174,413 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 31.83 per share. | 05 Apr 2021 | 953 | 13,754 (0%) | 0% | 31.8 | 30,332 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.02 per share. | 02 Apr 2021 | 380 | 14,707 (0%) | 0% | 32.0 | 12,168 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 28.61 per share. | 03 Mar 2021 | 172 | 15,087 (0%) | 0% | 28.6 | 4,921 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.70 per share. | 01 Mar 2021 | 88 | 15,259 (0%) | 0% | 27.7 | 2,438 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 256,850 | 256,850 | - | - | Non-Qualified Stock Option (right to buy) | |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.99 per share. | 14 Feb 2021 | 23,614 | 281,568 (0%) | 0% | 44.0 | 1,038,780 | Common Stock |
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 10 Feb 2021 | 6,000 | 6,000 | - | - | Stock Options | ||
| BCB Bancorp Inc (NJ) | James E. Collins | Director | 10 Feb 2021 | 2,400 | 91,788 (0%) | 0% | 0 | Common Stock | ||
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 22.26 per share. | 12 Jan 2021 | 1,680 | 15,347 (0%) | 0% | 22.3 | 37,403 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.69 per share. | 10 Jan 2021 | 857 | 17,027 (0%) | 0% | 21.7 | 18,588 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Sale of securities on an exchange or to another person at price $ 11.07 per share. | 29 Sep 2020 | 1,519 | 17,884 (0%) | 0% | 11.1 | 16,817 | Common Stock |
| Customers Bancorp Inc | James T. Collins | Chief Administrative Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.89 per share. | 26 Sep 2020 | 605 | 19,403 (0%) | 0% | 10.9 | 6,588 | Common Stock |
| Corteva Inc | James C. Collins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.48 per share. | 29 Jul 2020 | 60,897 | 304,229 (0%) | 0% | 28.5 | 1,734,347 | Common Stock |
| Fulcrum Therapeutics Inc | James J. Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 9,285 | 9,285 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges